Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tabletsare not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population. alfuzosin hydrochloride extended-release tabletsare contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [s ee use in specific populations (8.7) and clinical pharmacology (12.3 )]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [ see drug interactions (7.1 ) and clinical pharmacology (12.3 )] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzosin hydrochloride extended-release tablets [see

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

avkare, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physicians total care, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - uroxatral is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. uroxatral is not indicated for the treatment of hypertension. uroxatral is not indicated for use in the pediatric population. uroxatral is contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations (8.7) and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of uroxatral tablets [see adverse reactions (6.2)] pregnancy category b. uroxatral is not indicated for use in women, and there are no studies of alfuzosin in pregnant women alfuzosin was not teratogenic, embryotoxic or

Irska - engleski - HPRA (Health Products Regulatory Authority)

rowex ltd - alfuzosin hydrochloride - prolonged-release tablet - 10 milligram(s) - alpha-adrenoreceptor antagonists; alfuzosin

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

stat rx usa - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - uroxatral is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. uroxatral is not indicated for the treatment of hypertension. the recommended dosage is one 10 mg uroxatral (alfuzosin hcl) extended-release tablet once daily. the extent of absorption of uroxatral is 50% lower under fasting conditions. therefore, uroxatral should be taken immediately after the same meal each day. the tablets should not be chewed or crushed. uroxatral (alfuzosin hcl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with x10. uroxatral is contraindicated for use in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients. [see clinical pharmacology (12.3)]. uroxatral is contraindicated for use with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

golden state medical supply, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in the pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [ see use in specific populations ( 8.7) and clinical pharmacology ( 12.3) ].  in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [ see use in specific populations ( 8.7) and clinical pharmacology ( 12.3) ].  - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, a

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

concordia pharmaceuticals inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - uroxatral is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. uroxatral is not indicated for the treatment of hypertension. uroxatral is not indicated for use in the pediatric population. uroxatral is contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations (8.7) and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of uroxatral tablets [see adverse reactions (6.2)] risk summary uroxatral is not indicated for use in women. there are no adequate data on the developmental risk associated with use of uroxatral in pregnant women. b

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - alfuzosin hydrochloride - oral tablet - 2.5mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - alfuzosin hydrochloride - oral tablet - 2.5mg